Roche Holding (ROG.SW) Stock Price
Roche Holding Price
Roche Holding (ROG.SW) Stock | ISIN CH1499059983 | WKN 855167. The current Roche Holding stock price is 320 CHF (2026). Revenue is 63.83 B CHF. Net income is 16.55 B CHF. The P/E ratio is 15.52. Market capitalization is 256.96 B CHF. Roche Holding operates in the Health sector.
Roche Holding stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Roche Holding over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Roche Holding stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Roche Holding's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Roche Holding Price |
|---|
Roche Holding Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Roche Holding Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M CHF) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M CHF) |
| NET INCOME (M CHF) |
| NET INCOME GROWTH (%) |
| DIVIDEND (CHF)DIV. (CHF) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Roche Holding generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Roche Holding retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Roche Holding's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Roche Holding has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Roche Holding's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Roche Holding stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Roche Holding Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Roche Holding business model & stock analysis
Roche Holding SWOT Analysis
Strengths
Roche Holding AG has several strengths that contribute to its success:
- Strong brand reputation and recognition in the pharmaceutical industry.
- Diverse portfolio of innovative and life-saving drugs.
- Extensive research and development capabilities.
- Global presence with a wide network of subsidiaries and partnerships.
- Highly skilled and experienced workforce.
- Strong financial performance with consistent revenue growth.
Weaknesses
While Roche has many strengths, it also faces certain weaknesses:
- Dependence on a few key drugs for a significant portion of its revenue.
- High costs associated with drug development and clinical trials.
- Regulatory hurdles and the risk of litigation in the pharmaceutical industry.
- Relatively low diversification outside the pharmaceutical sector.
- Vulnerable to fluctuations in exchange rates and economic conditions.
Opportunities
Roche Holding AG can capitalize on the following opportunities:
- Increasing global demand for personalized medicine and targeted therapies.
- Expanding into emerging markets with growing healthcare needs.
- Investing in digital health and innovative technologies.
- Acquiring or partnering with smaller biotech companies for portfolio expansion.
- Collaborating with research institutions and academia for breakthrough discoveries.
Threats
Roche Holding AG should be cautious of the following threats:
- Intense competition from other pharmaceutical giants.
- Loss of patent protection and entry of generic competitors.
- Increasing regulatory scrutiny and pricing pressures.
- Political and legal uncertainties affecting international operations.
- Rapidly evolving technological landscape disrupting traditional business models.
Roche Holding Eulerpool Fair Value
Roche Holding historical P/E ratio, EBIT multiple, and P/S ratio
Roche Holding annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Roche Holding shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Roche Holding Dividend History
36 years of dividend payments · 23 consecutive increases
Roche Holding dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Roche Holding dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Roche Holding Earnings Estimates
Roche Holding Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 1/31/2024 | 8.2CHF | 29.52 BCHF | 2023 Q4 |
| 7/19/2023 | 11.46CHF | 32.24 BCHF | 2023 Q2 |
| 2/1/2023 | 9.14CHF | 32.3 BCHF | 2022 Q4 |
| 7/21/2022 | 11.12CHF | 30.93 BCHF | 2022 Q2 |
| 2/3/2022 | 9.81CHF | 32.2 BCHF | 2021 Q4 |
| 7/22/2021 | 10.41CHF | 30.67 BCHF | 2021 Q2 |
| 2/4/2021 | 8.93CHF | 30.95 BCHF | 2020 Q4 |
| 7/23/2020 | 10.73CHF | 30.66 BCHF | 2020 Q2 |
| 1/30/2020 | 9.07CHF | 32.32 BCHF | 2019 Q4 |
| 7/25/2019 | 10.79CHF | 30.01 BCHF | 2019 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Roche Holding stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Roche Holding shareholder structure
| % | Name |
|---|---|
3.11665% | |
2.24901% | |
1.93169% | |
1.79956% | |
1.50661% | |
1.35183% | |
1.33776% | |
1.07413% | |
0.81202% | |
0.68875% |
Roche Holding Executives and Management Board
Dr. Thomas Schinecker
(50)Chief Executive Officer, Member of the Corporate Executive Committee
Dr. Alan Hippe
(58)Chief Financial Officer, Member of the Corporate Executive Committee
Ms. Teresa Graham
(52)Member of the Corporate Executive Committee, Chief Executive Officer of Roche Pharmaceuticals
Dr. Severin Schwan
(58)Non-Executive Chairman of the Board · since 2006
Ms. Cristina Wilbur
(58)Member of the Corporate Executive Committee, Chief People Officer
Frequently asked questions about Roche Holding
Roche Holding stock
Roche Holding Peer Group
Roche Holding Ticker
Roche Holding FIGI
All fundamentals and in-depth analysis of Roche Holding
Our stock analysis for Roche Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Roche Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.